Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Capecitabine in Advanced Gastric and Gastro-Esophageal Adenocarcinomas
NCT00177255Phase 2Terminated
- Sponsor
- University of Pittsburgh
- Start
- Apr 2005
- Primary completion
- Dec 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, capecitabine in gastric adenocarcinoma, gastroesophageal adenocarcinoma, sponsored by University of Pittsburgh. Started Apr 2005; status: terminated.
02
Drugs
docetaxelcapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT00177255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00177255.